Lapatinib for advanced or metastatic breast cancer

Oncologist

Volumn 17, Issue 4, 2012, Pages 536-542

  Opdam, Frans L ^a,b   Guchelaar, Henk Jan ^b   Beijnen, Jos H ^c,d   Schellens, Jan H M ^a,d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Breast cancer; Clinical pharmacology; EGFR; HER 2; Lapatinib; Review

Indexed keywords

ADENOSINE TRIPHOSPHATE; CAPECITABINE; CARBAMAZEPINE; CLARITHROMYCIN; CYTOCHROME P450 3A4; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ITRACONAZOLE; KETOCONAZOLE; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; TRASTUZUMAB; VORICONAZOLE;

ARTICLE; BREAST CANCER; BREAST METASTASIS; DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG USE; DRUG WITHDRAWAL; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERICUM PERFORATUM; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHARMACODYNAMICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; TANDEM MASS SPECTROMETRY; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84860156361     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0461     Document Type: Article

References (44)

1. European Medicines Agency. Tyverb® Summary of Product Characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000795/WC500044957.pdf, accessed July 20, 2011.
2. U.S. Food and Drug Administration. Tykerb® Approval Letter 13-3-2007. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022059s000_APPROV.pdf, accessed July 20, 2011.
3. U.S. Food and Drug Administration. Tykerb® Approval Letter 29-01-2010. Available at http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022059s007ltr.pdf, accessed July 20, 2011.
4. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:65-77.
5. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
6. Xia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-6263.
7. Ahn ER, Vogel CL. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat 2012;131:371-381.
8. Xia W, Liu LH, Ho P et al. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004;23:646-653.
9. Bai F, Freeman BB 3rd, Fraga CH et al. Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 2006;83:169-175.
10. Burris HA 3rd, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-5313.
11. Koch KM, Reddy NJ, Cohen RB et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 2009;27:1191-1196.
12. Medina PJ, Goodin S. Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008;30:1426-1447.
13. U.S. Food and Drug Administration. Tykerb® Clinical Pharmacology and Biopharmaceutics NDA review. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022059s000_ClinPharmR.pdf, accessed February 1, 2012.
14. Polli JW, Olson KL, Chism JP et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}- 6-[5-({[2(methylsulfonyl)ethyl]amino}methyl)-2- furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 2009;37:439-442.
15. Burris HA 3rd, Taylor CW, Jones SF et al. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 2009;15:6702-6708.
16. Teng WC, Oh JW, New LS et al. Mechanismbased inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol 2010;78:693-703.
17. Midgley RS, Kerr DJ, Flaherty KT et al. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol 2007;18:2025-2029.
18. Smith DA, Koch KM, Arya N et al. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2009;67:421-426.
19. Kelly H, Graham M, Humes E et al. Delivery of a healthy baby after first-trimester maternal exposure to lapatinib. Clin Breast Cancer 2006;7:339-341.
20. Wood ER, Truesdale AT, McDonald OB et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652-6659.
21. Capri G, Chang J, Chen SC et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 2010; 21:474-480.
22. U.S. Food and Drug Administration Center for Drug Evaluation and Research. Medical Review Tykerb®. 6-3-2007. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022059s000_MedR_P1.pdf, accessed July 20, 2011.
23. European Medicines Agency. Assessment Report for Tyverb®. Procedure No. EMEA H/C/795, 2008. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000795/WC500044960.pdf, accessed July 20, 2011.
24. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
25. Cameron D, Casey M, Press M et al. Aphase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-543.
26. Cameron D, Casey M, Oliva C et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: Final survival analysis of a phase III randomized trial. The Oncologist 2010;15: 924-934.
27. Johnston S, Pippen J, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-5546.
28. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-1130.
29. Di Leo A, Gomez HL, Aziz Z et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as firstline treatment for metastatic breast cancer, J Clin Oncol 2008;26:5544-5552.
30. National Institute for Health and Clinical Excellence (NICE). Advanced Breast Cancer: Diagnosis and Treatment. Available at http://www.nice.org.uk/nicemedia/live/11778/43414/43414.pdf, accessed July 20, 2011.
31. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009; 27:1999-2006.
32. von Minckwitz G, Schwedler K, Schmidt M et al. Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011;47:2273-2281.
33. National Institute for Health and Clinical Excellence (NICE). Final Appraisal Determination: Lapatinib for the Treatment of Women With Previously Treated Advanced or Metastatic Breast Cancer. Available at http://www.nice.org.uk/nicemedia/live/11731/49197/49197.pdf, accessed July 20, 2011.
34. National Institute for Health and Clinical Excellence (NICE). Liverpool Review and Implementation Group. Lapatinib and Trastuzumab in Combination With an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor Positive Breast Cancer Which Overexpresses HER-2. Available at http://www.nice.org.uk/nicemedia/live/12337/52179/52179.pdf, accessed July 20, 2011.
35. CFH-Rapport 11/34: Lapatinib (Tyverb®) in Combinatie met een Aromataseremmer. Available at http://www.cvz.nl/binaries/live/cvzinternet/hst_content/nl/documenten/cfh-rapporten/2011/cfh1106-lapatinibtyverb.pdf, accessed July 20, 2011.
36. Clayton AJ, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91:639-643.
37. Stemmler L, Kahlert S, Siekiera W et al. Brain metastases (BM) in patients treated with trastuzumab for HER2 overexpressing metastatic breast cancer (MBC): Incidence and survival. J Clin Oncol 2005; 23:131S.
38. Stemmler J, Schmitt M, Willems A et al. Brain metastases in HER2-overexpressing metastatic breast cancer: Comparative analysis of trastuzumab levels in serum and cerebrospinal fluid. J Clin Oncol 2006;24:64S.
39. Johnston SRD, Gelmon KA, Pivot XB et al. Ongoing clinical development of lapatinib in HER2- positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies. J Clin Oncol 2011;29(15 suppl):TPS105.
40. ClinicalTrials.gov ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D. Available at http://www.clinicaltrials.gov/ct2/show/NCT00490139?term=ALTTO&rank=1, accessed July 20, 2011.
41. ClinicalTrials.gov. Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer. Available at http://www.clinicaltrials.gov/ct2/show/NCT00374322?Term=NCT00374322&rank=1, accessed July 20, 2011.
42. ClinicalTrials.gov. Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study. Available at http://www.clinicaltrials.gov/ct2/show/NCT00553358?term=NEO-ALTTO&rank=1, accessed July 20, 2011.
43. Baselga J, Bardbury I, Eidtmann H et al. First Results of the NeoALTTO Trial (BIG 01-06 / EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer [abstract S3-3]. Presented at the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8-12, 2010.
44. Wikipedia. Bestand:Lapatinib.svg. Available at http://nl.wikipedia.org/wiki/Bestand:Lapatinib.svg, accessed July20, 2011.